Compare GROV & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | EDSA |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 51.5M |
| IPO Year | 2021 | 2018 |
| Metric | GROV | EDSA |
|---|---|---|
| Price | $1.04 | $4.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.60 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 98.4K | 55.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,716,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $0.72 |
| 52 Week High | $1.57 | $20.32 |
| Indicator | GROV | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.25 | 35.63 |
| Support Level | $0.86 | $1.34 |
| Resistance Level | $1.15 | $5.10 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 53.04 | 21.46 |
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.